Progress update of Vitaeâ€™s RORÎ³t inhibitor program

June 4, 2013 2:02 PM ET

- *Robust efficacy results achieved in multiple sclerosis mouse model with record-breaking speed*
- *Vitaeâ€™s time from initiation of program to animal proof-of-principle with qualified lead has consistently been less than 18 months*

FORT WASHINGTON, PA â€“ June 4, 2013 â€“ Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company discovering and developing novel, small molecule, first- and bestin-class compounds, today announced that it has achieved animal proof-of-principle of one of its ROR gamma t (RORÎ³t) inhibitor candidates in an experimental allergic encephalitis (EAE) mouse model of multiple sclerosis in only nine months, breaking the companyâ€™s previous record of 12 months. Vitae is studying its RORÎ³t inhibitors for the treatment of a wide range of autoimmune disorders, including rheumatoid arthritis, psoriasis, steroid-resistant asthma and multiple sclerosis.

In the study, VTP-xx1 significantly reduced the severity of disease at both 10 mg/kg and 30 mg/kg oral doses. The compound demonstrated decreases in multiple cytokines/cytokine receptors in vivo, and a 50-70 percent decrease in mRNA levels of interleukin-17A (IL-17A), interleukin-17F (IL-17F) and the receptor for interleukin-23 (IL-23R). The compound was well tolerated at all doses.

â€œWe are excited about these data as they show that Vitaeâ€™s discovery technology platform generates compounds that are safe and efficacious in a highly relevant animal model,â said Jeff Hatfield, CEO of Vitae. â€œOur RORÎ³t program is a great example of Vitaeâ€™s ability to rapidly and consistently innovate against difficult targets in high-impact therapeutic categories.â

Vitaeâ€™s structure-based drug discovery approach has consistently demonstrated superior speed and performance. Time from program initiation to animal proof-of-principle with a qualified lead has been less than 18 months in each of Vitaeâ€™s programs with hard-to-drug targets. The companyâ€™s speed in its RORï¿½t program bests that of its LXR program for atherosclerosis, which achieved animal proof-of-principle in 12 months.

RORï¿½t inhibits the production of IL-17, a pro-inflammatory cytokine that is a key contributor to the pathogenesis of autoimmune inflammatory diseasessuch as psoriasis, rheumatoid arthritis, multiple sclerosis and asthma. Focusing on a small molecule solution, in just six months Vitae was able to design and synthesize compounds that solve the most critical discovery challenges including potency, isotype selectivity and PK.

â€œWe look forward to advancing this program, which has the potential to be a first-in-class and best-in-class disease modifying agent for the treatment of autoimmune disease,â said Hatfield.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company discovering and developing a portfolio of novel, small molecule, best-in-class compounds that address important disease areas, including chronic kidney disease, diabetes, Alzheimerâ€™s disease, and inflammation / autoimmunity.

Vitae excels at structure-based drug discovery and combines a proprietary technical platform with the insights of world class scientists to advance best-in-class compounds for high value, hard-to-drug targets. The accuracy and speed of Vitaeâ€™s drug discovery platform has enabled the company to discover and advance attractive compounds in multiple therapeutics areas in a rapid and highly capital efficient manner.

For additional information, please visit the companyâ€™s website at www.vitaepharma.com.

###

MEDIA CONTACT:
Tony Plohoros
908.940.0135
tplohoros@6degreespr.com